Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer

Arturas Dobilas (arturasdobilas@gmail.com)  
Skånes universitetssjukhus Lund  https://orcid.org/0000-0001-6884-2640

Yilun Chen  
Lund University: Lunds Universitet

Miguel Alcaide  
Lund University: Lunds Universitet

Christian Brueffer  
Lund University: Lunds Universitet

Pia Leandersson  
Lund University: Lunds Universitet

Lao H Saal  
Lund University: Lunds Universitet

Christer Borgfeldt  
Lund University: Lunds Universitet

Research Article

Keywords:

Posted Date: July 15th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1770497/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

Circulating tumor DNA (ctDNA), which is shed from tumor cells into the blood, is a promising minimal-invasive method for cancer diagnostics and monitoring. The aim of this study was to evaluate preoperative ctDNA levels in the plasma of patients with ovarian cancer and correlate the levels to clinicopathological parameters and patient outcome.

Methods

Tumor DNA was extracted from ovarian tumor tissue from 41 patients. Targeted sequencing using a panel of 127 genes recurrently mutated in cancer was performed to identify candidate somatic mutations in the tumor DNA. SAGAsafe digital PCR (dPCR) assays targeting the candidate mutations were used to measure ctDNA levels in patient plasma samples, obtained prior to surgery, to evaluate ctDNA levels in terms of mutant copy number/mL and variant allele frequency.

Results

Somatic mutations were found in 24 tumors, of which seven were from patients with borderline, and 17 with invasive cancer diagnosis. TP53 was the most frequently mutated gene. Fifteen of 24 patients had detectable ctDNA levels in pre-operative plasma. Plasma ctDNA mutant concentration increased with higher stage (p_{trend} < 0.001). Cancer patients with more than 10 ctDNA mutant copies/mL in plasma prior to surgery had significantly worse overall survival (p = 0.008).

Conclusions

Measuring ctDNA in pre-operative plasma may be useful as a predictive biomarker for tumor staging and prognosis in ovarian cancer patients.

Introduction

Ovarian cancer is one of the most prevalent and lethal gynecological cancers with more than 300,000 new cases diagnosed and more than 200,000 deaths recorded in 2020 worldwide [1]. The 5-year survival rate of ovarian cancer has remained in the range of 40–50% in the past 20 years despite diagnostic and therapeutic advancements [2, 3]. When diagnosed early, the prognosis of ovarian cancer is much better, with a 5-year survival rate of 73–92% for tumors diagnosed at stage I, compared to < 6% for tumors diagnosed at stage IV [4, 5].

Early detection of minimal disease may inform early surgical intervention and improve the outcome for the patient. However, due to the lack of suitable biomarkers, effective screening of ovarian cancer is yet to be established. Population screening trials like the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) have been performed to improve screening to enable earlier diagnosis of ovarian cancer, however still no excellent screening method has been found [6, 7]. For women with average to high risk of developing ovarian cancer, transvaginal ultrasound (TVUS) and CA-125 and HE4 blood tests are advised for screening of the disease, but no significant improvement in survival has been observed with these tests [8]. Protein biomarkers and combinations of biomarkers have good sensitivity to indicate malignancy in women with pelvic mass, but the specificity needs to be improved when women with pelvic tumors are evaluated before surgery [9–11]. At follow up of ovarian cancer after primary treatment, analysis of CA-125 and HE4 in combination with computed tomography (CT) scan is usually performed when suspicion of relapse.

In recent years, cell-free circulating tumor DNA (ctDNA) has emerged as a promising tumor biomarker [12]. Through cell death, apoptosis, and other mechanisms, ctDNA is released into the bloodstream and can be used for diagnosis, monitoring of treatment response and/or resistance, detection of latent disease, and prediction of outcome [12, 13]. It has been reported that elevated preoperative total plasma cell free DNA levels are correlated to events of advanced epithelial ovarian carcinoma [14]. Advances in deep-sequencing technology enable comprehensive cataloguing of tumor-specific (somatic) chromosomal rearrangements and mutations, which can then be detected in follow-up plasma samples using mutation detection technologies [12, 15–17].

The aim of the study was to measure tumor-specific mutations in plasma in early-stage ovarian cancer and borderline ovarian tumors after targeted sequencing of primary tumor tissues and relate the ctDNA measurements to clinicopathological features and patient outcome. Tumor-specific mutations in ovarian tumors were identified by targeted sequencing, which informed ctDNA analyses in matched plasma samples using the ultrasensitive SAGAsafe digital PCR method.

Materials And Methods
Written informed consent was obtained from all study participants. Ethical approval was granted by the Ethical Review Board at the Faculty of Medicine, Lund University, Sweden. Dnr 495 2016 (amendment to Dnr 558-2004 and 94-2006). Peripheral plasma samples were obtained preoperatively (the day before surgery or the same day) from 41 patients admitted for primary surgery of adnexal masses to the Department of Obstetrics and Gynecology in Lund, Sweden, between October 2004 and December 2012. Fresh frozen tumor biopsies from the same patients were also obtained and all samples stored at ~80°C until analyzed. The 41 patients were selected as a representative sample of ovarian tumor patients from the biobank. All data were grouped according to tumor type and stage of cancer: Benign (B), Borderline (BOT) and ovarian cancer (OvCa Stage I-IV).

DNA from tumor samples was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen). Tumor DNA samples were sheared to an average of 250 bp using a Covaris ultrasonicator before generating Illumina-compatible sequencing libraries using the KAPA HyperPrep Kit (Roche). Total library yields were measured using Qubit and size distributions checked with BioAnalyzer (Agilent) before adding equimolar amounts of each library into pools subjected to target enrichment. Targeted regions of the 41 libraries were hybridized according to manufacturer protocol with the xGen Pan-Cancer Panel (Integrated DNA Technologies; IDT) containing 127 cancer-associated genes or a custom xGen Lockdown Probes panel covering exons and hotspots in 14 genes recurrently mutated in cancer (IDT). The hybridized libraries were sequenced on an Illumina NextSeq 550 or MiSeq instrument.

Sequencing data was processed using a Snakemake workflow [18] and Bioconda [19] software packages. Basecallers were demultiplexed by sample and converted to unmapped BAM format using Picard v2.21.1, and unique molecular barcodes (UMIs) were extracted using fgbio v0.7.0. Reads matching UMIs (allowing for a maximum 1 base mismatch) were collapsed to generate consensus reads. These were aligned to the hg38 version of the human reference genome using BWA v0.7.17 [20]. Variants were called using VarDict-Java v1.7.0 [21]. Annotation was performed using vcfanno v0.3.1 [22] and the data sources COSMIC v87 [23, 24], dbSNP build 151 [25], as well as the Swedish [26] and Danish [27] human variation databases. To remove germline variants and sequencing artifacts, all variant calls that were also found in normal samples from five healthy donors were filtered, and only retained candidate variants as somatic that a) passed basic VarDict-Java criteria ("PASS" variants), b) were not in sequence repeat regions, and c) were not known common germline variants in the population according to the dbSNP and COSMIC databases, and the Swedish and Danish variation data (defined as >1% population frequency).

Cell-free DNA was isolated from patient plasma samples using the QIAamp MinElute cfDNA kits (Qiagen). CA-125 was analyzed at the routine laboratory at Lund University Hospital with ELISA. For each patient, candidate somatic mutations were selected and SAGAsafe digital PCR (dPCR) assays were selected or developed (SAGA Diagnostics AB). All assays were validated using positive control tumor DNA and wild-type negative control DNA samples. One individual assay was selected for each patient. The SAGAsafe technology detects point mutations and small indels down to 0.001% variant allele frequency. These assays provide quantitative result in terms of mutant- and wild-type copy number and the mutant allele frequency (MAF) for an analyzed sample. The assays were developed and validated on an Illumina NextSeq 550 or MiSeq instrument.

ANOVA with Bonferroni correction as post hoc test and trends across ordered groups were analyzed using linear regression with log-transformed values. Overall survival probabilities were calculated using the Kaplan–Meier method and the log-rank test. All comparisons were two-sided, and 5% level of significance was used. The statistical analyses were performed using SPSS 26.0 (IBM).

**Results**

Patient data were grouped according to tumor type as follows: Benign (n = 6), BOT (n = 9) and ovarian cancers (n = 26). The benign group generally consisted of younger patients (mean age 48 years ±13.3) compared to the cancer group (mean 64 years ±11.9). Preoperative CA-125 level in the BOT group was 293.7 ±627.3 units/mL and in the cancer group 1264.3±1147.1 units/ml. Somatic mutations were found in 24 tumor samples (seven were in BOT and 17 in cancer patients).

The mutations detected in plasma were in TP53, KRAS, PIK3CA, and PIK3R1. Seven patients with stage III, three with stage IV and four with stages I and II of ovarian cancer had detectable ctDNA in the plasma. All serous cancer patients with detectable ctDNA showed TP53 mutations, and one serous borderline patient had a KRAS mutation in plasma. The concentration of ctDNA increased with higher stage ($p_{\text{trend}}<0.001$). Concentrations of ctDNA in stage III and IV were significantly higher compared with stage I ($p = 0.025$ and $p = 0.007$ respectively) (Fig. 2). Moreover, cancer patients with more than 10 mutant copies/mL in plasma showed significantly worse overall survival (OS, $p = 0.008$ by log-rank test) (Fig. 3).

**Discussion**

**Main Finding**

In this study ctDNA was measured in plasma samples from early-stage ovarian cancer patients and borderline ovarian tumor patients using the SAGAsafe dPCR technology. The plasma levels of ctDNA mutations were increased in patients with higher stage of disease. In patients with
ovarian cancer, higher levels of ctDNA in plasma were associated with worse OS. These results indicate that ctDNA analyzed in plasma can be useful pre-operatively both as a diagnostic and as a prognostic biomarker in ovarian cancer.

Value of ctDNA in ovarian cancer clinical practice

Specific genomic alterations in ctDNA can guide cancer treatment

**TP53:**

The most frequently mutated gene in these patients with ovarian tumors was *TP53*, especially in advanced stage OvCa. Several studies have shown that *TP53* mutations are significantly associated with advanced OvCa since they are found in more than 90% of the high-grade serous ovarian carcinomas [28]. Loss of p53 function makes cells unable to induce apoptosis and therefore primes these cells for transformation into malignancy. Most mutations are single-base substitutions distributed throughout the coding sequence. *TP53* mutations have been shown to be prognostic and targets for pharmacological intervention. In the current Swedish national guidelines (RCC), PARP inhibitors are recommended for use in treatment of BRCA-mutated epithelial ovarian cancer [29]. PARP inhibitors are effective in *BRCA*-mutated OvCa [29] and in other tumors with homologous recombination deficiency by inhibiting PARP1 DNA repair in cancers with a 8 mutation. Only a few studies have been performed to evaluate the efficacy of PARP inhibitors in terms of *TP53* status [30, 31] and it has been presumed that targeting mutant p53, which destabilizes PARP repair function, may impede the distant spread of cancer cells [32].

**KRAS:**

*KRAS* gene mutations were found in seven tissue specimens, and one was found in plasma ctDNA. *KRAS* is a member of the Ras family of oncogenes, which also includes two other genes: *HRAS* and *NRAS*. The proteins these genes encode play important roles in cell division, cell differentiation, and the self-destruction of cells (apoptosis). Six mutations in *KRAS* were found in borderline tumors. Low-grade serous carcinomas (LGSOC) may progress from borderline tumors with frequent mutations of the *KRAS, BRAF,* or *ERBB2* genes and lack of *TP53* mutations [33]. Two large multicenter trials studying MEK inhibitors in LGSOC demonstrated activity in LGSOC, especially in *KRAS*-mutated disease. Accordingly, MEK inhibitors could be an alternative treatment in LGSOC [34]. In patients with advanced malignant melanoma with *BRAF* mutations, *KRAS* inhibition (*KRASi*) has shown very good results [35]. In lung adenocarcinoma patients with co-occurring *TP53* mutations, clinical benefit has been demonstrated from PO-1 inhibitors and mutation status may guide anti-PD-1/PD-L1 immunotherapy [36].

Concordance between tumor DNA and ctDNA

Various plasma ctDNA technologies are being tested in academic and commercial laboratories [37]. Plasma ctDNA testing has a promising role in follow up as a tumor marker, especially when treatment is based or monitored on a gene mutation profile [38]. In this study, 15 out of 24 (62.5%) patients with tumor DNA mutations also had mutations detected in plasma ctDNA, in line with previous reports [39]. However, the possibility to detect ctDNA mutations in plasma depends on the morphology of the tumor, the stage of the disease, tumor burden, as well as DNA degradation [39, 40].

ctDNA in relation to stage

The plasma ctDNA mutant concentration increased with higher stage, which is in accordance with previous studies [41, 42]. In late-stage cancer, especially in abdominal organs such as colon, pancreas, or ovaries, ctDNA has been commonly detected in more than 60% of patients [43]. In this study ctDNA was detected in two patients in stage I OvCa. Interestingly, our study also detected ctDNA mutation in plasma in one patient with a borderline tumor, which has not previously been reported. Other studies observed that tumor volume assessed by CT imaging correlated with ctDNA levels in patients with relapsed high-grade serous ovarian cancer [44, 45]. Patients with advanced ovarian cancer have had median concentrations of 100–1,000 mutated gene copies per 5 ml of plasma [45]. The analyses in this study were able to detect less than 10 copies/mL in plasma in early stage of disease, indicating very high sensitivity. Our and previous observations indicate that the amount of ctDNA in plasma relates to tumor volume and stage of disease.

**ctDNA mutations/mL plasma as prognostic factor**

Our results showed that patients in advanced stage of ovarian cancer had more mutated gene copies than in early stage of disease. The prognosis for ovarian cancer patients is highly related to stage [46]. Similar studies with gynecologic cancers have found that higher percentage of ctDNA correlated with worse survival [47]. In addition, higher ctDNA concentration significantly correlated with worse progression-free survival (PFS) [48]. Our results showed that patients with more than 10 ctDNA mutation copies/mL plasma had significantly worse overall survival. This indicates that the amount of ctDNA in plasma may be used as a prognostic marker.

Limitations of the study

This study needs to be validated in larger patient cohorts to confirm and reproduce our results before clinical implementation. Only genetic variants in the coding regions of genes were investigated. Previous studies have found that variants located in the intronic, and non-coding regions of
genomes may play a role in identifying individuals at genetic risk of developing ovarian cancer [49, 50]. Thus, this and other sequencing studies have limitations in identifying genetic variants associated with OvCa in non-coding regions.

In this study tumor material was available to sequence candidate somatic mutations for analyses of ctDNA in plasma. If no tumor material can be sequenced, and tumor-specific mutations analyzed, broad genomic panels must be designed for analyses of ctDNA in plasma.

**Main Conclusion**

This study found that ctDNA mutation could be detected in 15 out of 24 patients with ovarian cancer and premalignant ovarian borderline tumors. The most mutated gene was *TP53*. The concentration of ctDNA mutated copies in plasma was related to stage and was higher in advanced ovarian cancer stages. Patients with an increased amount of ctDNA in plasma experienced worse overall survival. Plasma is easily accessible and ctDNA may be used both for prediction of prognosis.

**Abbreviations**

cfDNA - Cell-free DNA  
ctDNA- circulating tumor-specific somatic DNA  
*BRAF*- B-Raf Proto-Oncogene, Serine/Threonine Kinase  
CA-125 – Cancer Antigen 125  
HE4 – Human Epididymis Protein 4  
KIT - Proto-oncogene c-KIT  
*KRAS* - Kirsten Rat Sarcoma Viral Proto-Oncogene  
*PIK3CA* - Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha  
*PIK3R1*- Phosphoinositide-3-Kinase Regulatory Subunit  
*TP53*- Tumor Protein P53

**Declarations**

**Acknowledgments**

We are grateful to all the patients who participated in this study, to the staff at the Department of Obstetrics and Gynecology, Lund University Hospital, for assistance with collecting the blood samples and to the laboratory staff at the Division of Oncology.

**Author contributions**

Arturas Dobilas: Study conception and design; data acquisition, analysis, and interpretation; drafting and revising the manuscript.  
Pia Leandersson: Data acquisition and revising the manuscript.  
Yilun Chen: Data acquisition, analysis, and interpretation; drafting and revising the manuscript.  
Miguel Alcaide: Data acquisition, analysis, and interpretation; drafting and revising the manuscript.  
Christian Brueffer: Data acquisition, analysis, and interpretation; drafting and revising the manuscript.  
Lao H Saal: Study conception and design; data acquisition, analysis, and interpretation; revising the manuscript.  
Christer Borgfeldt: Study conception and design; data acquisition, analysis, and interpretation; revising the manuscript.

**Funding:** The study was supported by funds from the Swedish Cancer Foundation and Regional Funds Region Skåne. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Consent for publication:** All authors agree to publish this article.

**Competing interests:** The authors declare no competing interests.
Availability of data and materials: All data were obtained according to the Swedish Act concerning the Ethical Review of Research Involving Humans to ensure confidentiality and are available on reasonable request.

Competing interests: The authors are solely responsible for the content and writing of the paper. Lao H Saal has received honoraria from Novartis and Boehringer-Ingelheim. Yilun Chen, Miguel Alcaide, Christian Brueffer and Lao H Saal have ownership interests in SAGA Diagnostics. The authors declare that they have no conflicts of interest.

References

1. International Agency for Research on Cancer [https://gco.iarc.fr/today/fact-sheets-cancers].


### Tables

**Table 1.** Genetic mutations found in the tumors related to hysto-pathology.

<table>
<thead>
<tr>
<th>Gene mutations</th>
<th>Benign</th>
<th>Endometriosis</th>
<th>Teratoma</th>
<th>Serous</th>
<th>Serous</th>
<th>Endometrioid</th>
<th>Endometrioid</th>
<th>Mucinous</th>
<th>Mucinous</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>In tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>KRAS</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>ASXL1*</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>BRAF</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>FLT3*</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>KIT*</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PIK3R1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>No detected</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>13</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>13</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>1</td>
<td>41</td>
</tr>
</tbody>
</table>

*Germline mutation

### Figures
Figure 1
Waterfall plot of validated somatic mutations in the patient tumors. Genes are indicated in rows, and samples in columns. Mutated samples are shown according to mutation type. Patient and tumor clinicopathological variables are shown below the patient IDs.

Figure 2
Plasma circulating tumor DNA (ctDNA) mutant concentration increased with higher stage ($p_{\text{trend}} \leq 0.001$). Concentrations of circulating tumor DNA (ctDNA) in stage III and stage IV OvCa were significantly higher compared with stage I OvCa ($p = 0.025$ and $p=0.007$ respectively). Bars include highest and lowest values, except outliers ($\bigcirc$), which are 1.5 to 3 box lengths from the end of the box, and extremes ($*$) which are more than 3 box lengths from the end of the box.
Figure 3

Kaplan Meier analysis of overall survival in patients related to genetic mutation found in plasma. Patients with 10 or more ctDNA mutations/mL (red line) plasma had significantly worse overall survival than patients with fewer than 10 ctDNA mutations/ml (blue line) (OS, p=0.008 by log-rank test).